

# Ming-Zhi Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7628698/publications.pdf>

Version: 2024-02-01

217  
papers

3,978  
citations

186265

28  
h-index

206112

48  
g-index

228  
all docs

228  
docs citations

228  
times ranked

5768  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system. <i>Hematological Oncology</i> , 2023, 41, 267-274.	1.7	3
2	Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma. <i>Hematological Oncology</i> , 2023, 41, 257-266.	1.7	4
3	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 42-50.	0.6	2
4	Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. <i>European Journal of Cancer</i> , 2022, 164, 117-126.	2.8	27
5	Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation. <i>Leukemia and Lymphoma</i> , 2022, , 1-6.	1.3	0
6	Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study. <i>Investigational New Drugs</i> , 2022, 40, 650-659.	2.6	19
7	IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4. <i>Investigational New Drugs</i> , 2022, 40, 537-545.	2.6	5
8	Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase III trial. <i>American Journal of Hematology</i> , 2022, 97, 623-629.	4.1	15
9	The potential efficacy and mechanism of bendamustine in extranodal NK/T cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 678-688.	1.7	0
10	CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes. <i>Leukemia Research</i> , 2022, 117, 106840.	0.8	3
11	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 846357.	3.5	5
12	The Effect of Chronic Rhinosinusitis on the Staging and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 878559.	2.8	1
13	A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents. <i>Scientific Reports</i> , 2022, 12, 7118.	3.3	1
14	Hsa_circ_0023984 Regulates Cell Proliferation, Migration, and Invasion in Esophageal Squamous Cancer via Regulating miR-1294/PI3K/Akt/c-Myc Pathway. <i>Applied Biochemistry and Biotechnology</i> , 2022, 194, 1-16.	2.9	3
15	Efficacy and Safety of a Pegasparginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma. <i>JAMA Oncology</i> , 2022, 8, 1035.	7.1	21
16	Non-invasive detection of lymphoma with circulating tumor DNA features and plasma protein marker.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19574-e19574.	1.6	0
17	Abstract 5111: Prompt assessment of molecular tumor load and treatment response in patients with lymphoma by a blood-based multi-omics approach. <i>Cancer Research</i> , 2022, 82, 5111-5111.	0.9	0
18	Two-year follow-up result of RELIANCE study, a multicenter phase 2 trial of relmacabtagene autoleucl in Chinese patients with relapsed/refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7529-7529.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Prompt assessment of tumor load and treatment response in patients with lymphoma by a blood-based multiomics approach.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19547-e19547.	1.6	0
20	Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 941-952.	1.7	1
21	MYD88 L265P elicits mutation-specific ubiquitination to drive NF- $\kappa$ B activation and lymphomagenesis. <i>Blood</i> , 2021, 137, 1615-1627.	1.4	21
22	Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T $\alpha$ cell lymphoma: A randomized, controlled, open $\alpha$ label, multicenter study. <i>International Journal of Cancer</i> , 2021, 148, 1470-1477.	5.1	10
23	DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T $\alpha$ cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. <i>Clinical and Translational Science</i> , 2021, 14, 405-411.	3.1	8
24	Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial. <i>Cancer Biology and Medicine</i> , 2021, 19, 1089-1099.	3.0	1
25	Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFR $\beta$ pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: Functional validation and clinical theranostic significance. <i>International Journal of Biological Sciences</i> , 2021, 17, 1061-1078.	6.4	34
26	Emerging Roles for the Gut Microbiome in Lymphoid Neoplasms. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110241.	1.3	8
27	Updating targets for natural killer/T-cell lymphoma immunotherapy. <i>Cancer Biology and Medicine</i> , 2021, 18, 52-62.	3.0	12
28	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	17.0	40
29	New prognostic models for extranodal natural killer T-cell lymphoma, nasal-type using Cox regression and machine learning. <i>Translational Cancer Research</i> , 2021, 10, 613-626.	1.0	2
30	Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells. <i>Cancer Cell International</i> , 2021, 21, 191.	4.1	18
31	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1509-1516.	1.8	11
32	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr $\alpha$ m macroglobulinemia. <i>Neoplasia</i> , 2021, 23, 361-374.	5.3	16
33	Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients. <i>Pathology and Oncology Research</i> , 2021, 27, 589662.	1.9	3
34	Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate. <i>Scientific Reports</i> , 2021, 11, 11220.	3.3	7
35	Hydroa vacciniforme $\alpha$ like lymphoproliferative disorder: A clinicopathological, immunohistochemical, and prognostic study of 24 cases in China. <i>Journal of Dermatology</i> , 2021, 48, 1315-1326.	1.2	3
36	Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. <i>Chinese Medical Journal</i> , 2021, 134, 1299-1309.	2.3	4

#	ARTICLE	IF	CITATIONS
37	Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure. <i>Frontiers in Oncology</i> , 2021, 11, 687374.	2.8	9
38	Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 663961.	2.8	4
39	A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China. <i>Chinese Medical Journal</i> , 2021, 134, 1584-1592.	2.3	1
40	LncRNA MEG3 regulates breast cancer proliferation and apoptosis through miR-141-3p/RBMS3 axis. <i>Genomics</i> , 2021, 113, 1689-1704.	2.9	29
41	Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma. <i>Cancer Research and Treatment</i> , 2021, 53, 837-846.	3.0	9
42	Significant Diagnostic and Prognostic Value of FLAD1 and Related MicroRNAs in Breast Cancer after a Pan-Cancer Analysis. <i>Disease Markers</i> , 2021, 2021, 1-21.	1.3	3
43	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF- $\kappa$ B/P65 pathway. <i>Environmental Toxicology and Pharmacology</i> , 2021, 85, 103639.	4.0	6
44	Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 686595.	3.9	3
45	GNPMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/ $\beta$ -catenin signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , 2021, 710, 108998.	3.0	6
46	Suppression of latent transforming growth factor- $\beta$ 2 (TGF- $\beta$ 2)-binding protein 1 (LTBP1) inhibits natural killer/ T cell lymphoma progression by inactivating the TGF- $\beta$ 2/Smad and p38MAPK pathways. <i>Experimental Cell Research</i> , 2021, 407, 112790.	2.6	13
47	Relmacabtagene autoleucel (relma $\epsilon$ cel) CD19 CAR $\epsilon$ T therapy for adults with heavily pretreated relapsed/refractory large B $\epsilon$ cell lymphoma in China. <i>Cancer Medicine</i> , 2021, 10, 999-1011.	2.8	50
48	CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3. <i>Cancer Cell International</i> , 2021, 21, 594.	4.1	5
49	The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells. <i>Blood</i> , 2021, 138, 3830-3830.	1.4	3
50	Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Na $\acute{v}$ e Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study. <i>Blood</i> , 2021, 138, 2480-2480.	1.4	0
51	Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial. <i>Blood</i> , 2021, 138, 1368-1368.	1.4	1
52	Fotemustine-Containing Regimens Versus Regimens Based on High-Dose Methotrexate in Newly Diagnosed PCNSL. <i>Blood</i> , 2021, 138, 4559-4559.	1.4	0
53	Analysis of the Tumor Microenvironment By Quantitative Immunohistochemistry Reveals Novel Predictors in Classic Hodgkin Lymphoma Treated with Anti-PD1 Therapy. <i>Blood</i> , 2021, 138, 4530-4530.	1.4	0
54	Integrating Circulating Tumor DNA Features and Plasma Protein Markers to Detected Early Lymphoid Neoplasm. <i>Blood</i> , 2021, 138, 4489-4489.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The Synergistic Anticancer Effect of a Combination of Chidamide and Etoposide Against NK/T Cell Lymphoma. <i>Blood</i> , 2021, 138, 3987-3987.	1.4	2
56	A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 3829-3829.	1.4	13
57	Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12206-12216.	0.0	0
58	Potential strategies against resistance to CAR T-cell therapy in haematological malignancies. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096296.	3.2	7
59	Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. <i>European Journal of Radiology</i> , 2020, 133, 109301.	2.6	9
60	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. <i>Clinical Epigenetics</i> , 2020, 12, 169.	4.1	40
61	&lt;p&gt;Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7189-7197.	2.0	13
62	Targeting PD-L1 in non-small cell lung cancer using CAR T cells. <i>Oncogenesis</i> , 2020, 9, 72.	4.9	48
63	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	17.0	27
64	CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 488.	2.8	11
65	Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. <i>Investigational New Drugs</i> , 2020, 38, 1847-1853.	2.6	28
66	Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) <i>versus</i> CHOP in newly diagnosed peripheral T-cell lymphoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092382.	3.2	9
67	Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. <i>Clinical Immunology</i> , 2020, 214, 108382.	3.2	40
68	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. <i>Leukemia</i> , 2020, 34, 2243-2248.	7.2	35
69	<p>Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 275-284.	4.3	6
70	Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma. <i>Haematologica</i> , 2020, 105, e107-e110.	3.5	7
71	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 38.	17.0	18
72	&lt;p&gt;High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 1903-1912.	1.9	19

#	ARTICLE	IF	CITATIONS
73	Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies. <i>Blood</i> , 2020, 136, 43-43.	1.4	11
74	Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2020, 136, 1-1.	1.4	13
75	First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3026-3026.	1.6	13
76	&lt;p&gt;Primary Causes of Death in Patients with Non-Hodgkinâ€™s Lymphoma: A Retrospective Cohort Study&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3155-3162.	1.9	5
77	A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. <i>Immunotherapy</i> , 2020, 12, 681-696.	2.0	14
78	Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8033-8033.	1.6	0
79	Outcomes of GDPT (gemcitabine, cisplatin, prednisone,thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8018-8018.	1.6	0
80	sATPâ€™binding cassette subfamilyï½2 memberï½2 enhances the multidrug resistance properties of human nasal natural killer/Tï½2cell lymphoma side population cells. <i>Oncology Reports</i> , 2020, 44, 1467-1478.	2.6	1
81	ORP8 induces apoptosis by releasing cytochromeï½2c from mitochondria in nonâ€™small cell lung cancer. <i>Oncology Reports</i> , 2020, 43, 1516-1524.	2.6	3
82	Selection of new immunotherapy targets for NK/T cell lymphoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 7034-7047.	0.0	6
83	Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway. <i>Blood</i> , 2020, 136, 46-47.	1.4	0
84	Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. <i>Blood</i> , 2020, 136, 39-40.	1.4	2
85	FOXC1 silencing inhibits the epithelialâ€™toâ€™mesenchymal transition of glioma cells: Involvement of Î²â€™catenin signaling. <i>Molecular Medicine Reports</i> , 2019, 19, 251-261.	2.4	15
86	Positive PDâ€™L1 expression is predictive for patients with advanced EGFR wildâ€™type nonâ€™small cell lung cancer treated with gemcitabine and cisplatin. <i>Oncology Letters</i> , 2019, 18, 161-168.	1.8	2
87	Non-coding RNAs in Natural Killer/T-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 515.	2.8	16
88	&lt;p&gt;Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 8277-8284.	1.9	0
89	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. <i>Nature Communications</i> , 2019, 10, 5061.	12.8	18
90	Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients. <i>Frontiers in Medicine</i> , 2019, 6, 237.	2.6	1

#	ARTICLE	IF	CITATIONS
91	High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. <i>Pathology Research and Practice</i> , 2019, 215, 152638.	2.3	17
92	Prognostic nomogram for overall survival in upper aerodigestive tract extranodal natural killer/T-cell lymphoma, nasal type, stages IE and IIE: A SEER-based study. <i>Oncology Letters</i> , 2019, 18, 3493-3500.	1.8	2
93	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 33-43.	2.7	6
94	Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration. <i>Thoracic Cancer</i> , 2019, 10, 1962-1972.	1.9	13
95	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. <i>Nature Communications</i> , 2019, 10, 4209.	12.8	25
96	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	5.5	39
97	Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. <i>Cancer Medicine</i> , 2019, 8, 3892-3904.	2.8	23
98	Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III&ndash;IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus. <i>Cancer Management and Research</i> , 2019, Volume 11, 3555-3564.	1.9	15
99	Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. <i>Hematology</i> , 2019, 24, 440-445.	1.5	6
100	Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study. <i>PLoS ONE</i> , 2019, 14, e0214860.	2.5	8
101	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. <i>Cancer Management and Research</i> , 2019, Volume 11, 1363-1372.	1.9	8
102	Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12628-12637.	2.6	36
103	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	2.0	17
104	Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. <i>Oncologist</i> , 2019, 24, e1123-e1131.	3.7	22
105	Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN- $\gamma$ -associated JAK-STAT pathway. <i>Oncotargets and Therapy</i> , 2019, Volume 12, 2079-2088.	2.0	24
106	The clinical features and prognosis of 100 AIDS-related lymphoma cases. <i>Scientific Reports</i> , 2019, 9, 5381.	3.3	16
107	Circular METRN RNA hsa_circ_0037251 Promotes Glioma Progression by Sponging miR-1229-3p and Regulating mTOR Expression. <i>Scientific Reports</i> , 2019, 9, 19791.	3.3	26
108	CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation. <i>Cancer Management and Research</i> , 2019, Volume 11, 10215-10221.	1.9	20

#	ARTICLE	IF	CITATIONS
109	miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 9652-9662.	4.1	10
110	Recurrent PDGFRB mutations in unicentric Castleman disease. <i>Leukemia</i> , 2019, 33, 1035-1038.	7.2	48
111	One method to establish Epstein-Barr virus-associated <sc>NK</sc>/T cell lymphoma mouse models. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1509-1516.	3.6	5
112	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. <i>Cancer Biology and Therapy</i> , 2019, 20, 31-41.	3.4	32
113	Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2019, 134, 755-755.	1.4	21
114	Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labeled Study with Ddgp Regimen Versus SMILE Regimen. <i>Blood</i> , 2019, 134, 463-463.	1.4	11
115	Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 5221-5221.	1.4	1
116	GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin's lymphoma: Preliminary result of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14072-e14072.	1.6	2
117	Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China. <i>International Journal of Ophthalmology</i> , 2019, 12, 1731-1736.	1.1	8
118	Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts in vitro. <i>Aging</i> , 2019, 11, 573-589.	3.1	7
119	B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma. <i>Aging</i> , 2019, 11, 3939-3957.	3.1	6
120	Role of circular RNA in hematological malignancies (Review). <i>Oncology Letters</i> , 2019, 18, 4385-4392.	1.8	10
121	Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. <i>Translational Cancer Research</i> , 2019, 8, 2485-2495.	1.0	5
122	Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 2851-2851.	1.4	0
123	Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study. <i>Blood</i> , 2019, 134, 2873-2873.	1.4	0
124	Latent Membrane Protein 1 Contributes to Deficient Cellular Immunity in NKTCL Patients. <i>Blood</i> , 2019, 134, 3969-3969.	1.4	0
125	Gelsolin regulates proliferation, apoptosis and invasion in NK/T-cell lymphoma cells. <i>Biology Open</i> , 2018, 7, .	1.2	8
126	Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature. <i>Oncology Letters</i> , 2018, 15, 8034-8038.	1.8	2



#	ARTICLE	IF	CITATIONS
127	Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngsters. <i>Scientific Reports</i> , 2018, 8, 1088.	3.3	10
128	SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma. <i>Experimental Cell Research</i> , 2018, 364, 125-132.	2.6	14
129	Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer. <i>Clinical Infectious Diseases</i> , 2018, 66, 1948-1952.	5.8	13
130	miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 58.	17.0	98
131	MYD88 L265P Mutation in Lymphoid Malignancies. <i>Cancer Research</i> , 2018, 78, 2457-2462.	0.9	92
132	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. <i>Oncogene</i> , 2018, 37, 3151-3165.	5.9	90
133	miR-455-3p serves as prognostic factor and regulates the proliferation and migration of non-small cell lung cancer through targeting HOXB5. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 1074-1080.	2.1	45
134	Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 406-410.	2.5	22
135	Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China. <i>Chinese Medical Journal</i> , 2018, 131, 1767-1775.	2.3	9
136	MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. <i>Anti-Cancer Drugs</i> , 2018, 29, 861-870.	1.4	8
137	Analyses and treatment of simultaneous B-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. <i>Oncology Letters</i> , 2018, 16, 6624-6632.	1.8	8
138	Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. <i>Cancer Cell International</i> , 2018, 18, 150.	4.1	3
139	IL-13 Contributes to Drug Resistance of NK/T-Cell Lymphoma Cells by Regulating ABCC4. <i>BioMed Research International</i> , 2018, 2018, 1-9.	1.9	5
140	Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T cell lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 4772-4778.	1.8	1
141	AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. <i>Molecular Medicine</i> , 2018, 24, 35.	4.4	18
142	Platelet-derived growth factor receptor alpha (PDGFR $\alpha$ ) is overexpressed in NK/T-cell lymphoma and mediates cell survival. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 525-531.	2.1	10
143	B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma. <i>Scientific Reports</i> , 2018, 8, 12907.	3.3	13
144	Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (glycol)-poly(lactide- Anti-Cancer Drugs, 2018, 29, 637-645.	1.4	13

#	ARTICLE	IF	CITATIONS
145	Bushenshugan Formula Attenuates the Development of Lung Cancer by Inhibiting Epithelial-Mesenchymal Transition. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 1977-1988.	1.6	10
146	Long Noncoding RNA PlncRNA-1 Promotes Colorectal Cancer Cell Progression by Regulating the PI3K/Akt Signaling Pathway. <i>Oncology Research</i> , 2018, 26, 261-268.	1.5	47
147	Lymphoma associated hemophagocytic syndrome: A single-center retrospective study. <i>Oncology Letters</i> , 2018, 16, 1275-1284.	1.8	28
148	High SRPX2 protein expression predicts unfavorable clinical outcome in patients with prostate cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3149-3157.	2.0	11
149	Dual TGF $\beta$ 2 and PD $\beta$ 1 blockade synergistically enhances MAGEA3-specific CD8 <sup>+</sup> T cell response in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2561-2574.	5.1	68
150	Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1265-1277.	2.5	5
151	TlPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/ $\beta$ 2-catenin pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 7.	4.4	19
152	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 15.	17.0	155
153	Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat diet. <i>RSC Advances</i> , 2018, 8, 16636-16644.	3.6	2
154	IL-13 and IL-13R $\beta$ 1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 2715-2720.	2.1	5
155	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. <i>Journal of Neuro-Oncology</i> , 2018, 140, 427-434.	2.9	22
156	An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 16213-16219.	1.8	10
157	A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 7552-7552.	1.6	0
158	Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. <i>Scientific Reports</i> , 2017, 7, 41057.	3.3	23
159	Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , 2017, 13, 1211-1215.	1.8	12
160	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. <i>Scientific Reports</i> , 2017, 7, 682.	3.3	24
161	The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. <i>British Journal of Haematology</i> , 2017, 178, 772-780.	2.5	25
162	Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. <i>International Journal of Hematology</i> , 2017, 106, 612-621.	1.6	14

#	ARTICLE	IF	CITATIONS
163	Pretreatment 14â€³â€³ epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginaseâ€³based chemotherapy. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600111.	1.6	10
164	RING box protein-1 gene involved in flagellar disassembly of <i>Dunaliella salina</i> . <i>Folia Microbiologica</i> , 2017, 62, 57-62.	2.3	0
165	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	4.8	225
166	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. <i>Oncotarget</i> , 2017, 8, 7201-7207.	1.8	27
167	Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype <i>in vitro</i> and malignant features in esophageal squamous cell carcinomas. <i>Oncotarget</i> , 2017, 8, 1058-1073.	1.8	36
168	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway. <i>Oncotarget</i> , 2017, 8, 10954-10965.	1.8	13
169	Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers. <i>Oncotarget</i> , 2017, 8, 13344-13356.	1.8	25
170	Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells. <i>Oncotarget</i> , 2017, 8, 46363-46380.	1.8	50
171	Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. <i>Oncotarget</i> , 2017, 8, 72182-72196.	1.8	43
172	The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>Oncotarget</i> , 2016, 7, 58396-58404.	1.8	20
173	Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study. <i>BMC Cancer</i> , 2016, 16, 537.	2.6	11
174	<i>PDHA1</i> gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence. <i>Oncotarget</i> , 2016, 7, 53837-53852.	1.8	29
175	Effects of microRNA-21 on the biological functions of T-cell acute lymphoblastic lymphoma/leukemia. <i>Oncology Letters</i> , 2016, 12, 4173-4180.	1.8	12
176	Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: A case report. <i>Oncology Letters</i> , 2016, 12, 611-614.	1.8	5
177	DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China. <i>Clinical Cancer Research</i> , 2016, 22, 5223-5228.	7.0	112
178	ADAM10 mediates the cell invasion and metastasis of human esophageal squamous cell carcinoma via regulation of E-cadherin activity. <i>Oncology Reports</i> , 2016, 35, 2785-2794.	2.6	12
179	S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine. <i>Scientific Reports</i> , 2016, 6, 23695.	3.3	28
180	MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer. <i>BMC Cancer</i> , 2016, 16, 894.	2.6	31

#	ARTICLE	IF	CITATIONS
181	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. <i>Journal of Hematology and Oncology</i> , 2016, 9, 21.	17.0	181
182	Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. <i>Oncology Letters</i> , 2016, 11, 693-698.	1.8	13
183	RelA NF- $\kappa$ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	3.1	29
184	Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149. <i>Oncotarget</i> , 2016, 7, 55721-55731.	1.8	19
185	MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 53808-53819.	1.8	21
186	Generation of TALEN-mediated FH knockout rat model. <i>Oncotarget</i> , 2016, 7, 61656-61669.	1.8	14
187	Establishment of mitochondrial pyruvate carrier 1 (MPC1) gene knockout mice with preliminary gene function analyses. <i>Oncotarget</i> , 2016, 7, 79981-79994.	1.8	17
188	GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975). <i>Blood</i> , 2016, 128, 2989-2989.	1.4	0
189	Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma. <i>American Journal of Cancer Research</i> , 2016, 6, 2076-2087.	1.4	3
190	Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2016, 36, 343-9.	1.1	6
191	Therapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature. <i>Oncology Letters</i> , 2015, 10, 3261-3265.	1.8	8
192	Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells <i>in vitro</i> . <i>Oncotarget</i> , 2015, 6, 37758-37769.	1.8	57
193	Inhibition of cell proliferation and metastasis of human hepatocellular carcinoma by miR-137 is regulated by CDC42. <i>Oncology Reports</i> , 2015, 34, 2523-2532.	2.6	17
194	Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis. <i>International Journal of Molecular Medicine</i> , 2015, 36, 1335-1344.	4.0	22
195	TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 638-643.	2.1	39
196	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	17.0	84
197	Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2613-2618.	1.3	12
198	ATP-binding cassette sub-family C member 4 (ABCC4) is overexpressed in human NK/T-cell lymphoma and regulates chemotherapy sensitivity: Potential as a functional therapeutic target. <i>Leukemia Research</i> , 2015, 39, 1448-1454.	0.8	18

#	ARTICLE	IF	CITATIONS
199	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 104.	17.0	139
200	Prognostic impact of c-Rel nuclear expression and c-REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	1.8	35
201	ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro. <i>Oncotarget</i> , 2015, 6, 42687-42703.	1.8	19
202	Six1 promotes glioblastoma cell proliferation and invasion by upregulation of connective tissue growth factor. <i>American Journal of Cancer Research</i> , 2015, 5, 1823-30.	1.4	10
203	Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 14875-84.	0.5	18
204	Decreased Expression of PDHE1 $\beta$ Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2015, 35, 5533-8.	1.1	10
205	A retrospective study of external beam radiation, neutron brachytherapy, and concurrent chemotherapy for patients with localized advanced carcinoma of the esophagus. <i>Radiation Oncology</i> , 2014, 9, 294.	2.7	3
206	Asparagine synthetase expression and its potential prognostic value in patients with NK/T cell lymphoma. <i>Oncology Reports</i> , 2014, 32, 853-859.	2.6	15
207	miRNA-155 modulates the malignant biological characteristics of NK/T-cell lymphoma cells by targeting FOXO3a gene. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2014, 34, 882-888.	1.0	16
208	Peroxiredoxin 1 is involved in disassembly of flagella and cilia. <i>Biochemical and Biophysical Research Communications</i> , 2014, 444, 420-426.	2.1	11
209	Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. <i>Oncology Letters</i> , 2014, 8, 1461-1469.	1.8	46
210	Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report. <i>Oncology Letters</i> , 2014, 8, 886-890.	1.8	4
211	A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 5475-5475.	1.4	0
212	a Proposal for a New Staging System of Extranodal Natural Killer T-cell Lymphoma, Nasal-Type: a Multicenter Study of Chinese Southwest Oncology Group (CSWOG). <i>Blood</i> , 2014, 124, 4444-4444.	1.4	0
213	Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 631-9.	0.5	15
214	Cancer stem cells as a potential therapeutic target in breast cancer. <i>Stem Cell Investigation</i> , 2014, 1, 14.	3.0	7
215	The effects and mechanism of action of <i>Prunella vulgaris</i> L extract on Jurkat human T lymphoma cell proliferation. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 426-429.	0.1	15
216	Humoral immunoreaction induced by TCR DNA vaccine for $\beta$ chain of T cell lymphoma. <i>Vaccine</i> , 2004, 22, 2031-2041.	3.8	3

#	ARTICLE	IF	CITATIONS
217	Short-Term effects of cinobufagin in the treatment of middle and advanced malignant tumors. , 1997, 3, 120-122.		0